These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15125957)

  • 1. N-Aryl-gamma-lactams as integrin alphavbeta3 antagonists.
    Xi N; Arvedson S; Eisenberg S; Han N; Handley M; Huang L; Huang Q; Kiselyov A; Liu Q; Lu Y; Nunez G; Osslund T; Powers D; Tasker AS; Wang L; Xiang T; Xu S; Zhang J; Zhu J; Kendall R; Dominguez C
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2905-9. PubMed ID: 15125957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part III: synthesis of potent antagonists with alpha(v)beta3/alpha(IIb)beta3 dual activity and improved water solubility.
    Ishikawa M; Hiraiwa Y; Kubota D; Tsushima M; Watanabe T; Murakami S; Ouchi S; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2131-50. PubMed ID: 16307881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
    Kubota D; Ishikawa M; Yamamoto M; Murakami S; Hachisu M; Katano K; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2089-108. PubMed ID: 16309911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
    Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tricyclic pharmacophore-based molecules as novel integrin alphavbeta3 antagonists. Part IV: preliminary control of alphavbeta3 selectivity by meta-oriented substitution.
    Kubota D; Ishikawa M; Ishikawa M; Yahata N; Murakami S; Fujishima K; Kitakaze M; Ajito K
    Bioorg Med Chem; 2006 Jun; 14(12):4158-81. PubMed ID: 16504518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.
    Wendt JA; Wu H; Stenmark HG; Boys ML; Downs VL; Penning TD; Chen BB; Wang Y; Duffin T; Finn MB; Keene JL; Engleman VW; Freeman SK; Hanneke ML; Shannon KE; Nickols MA; Steininger CN; Westlin M; Klover JA; Westlin W; Nickols GA; Russell MA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):845-9. PubMed ID: 16303301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.
    Anderluh M; Cesar J; Stefanic P; Kikelj D; Janes D; Murn J; Nadrah K; Tominc M; Addicks E; Giannis A; Stegnar M; Dolenc MS
    Eur J Med Chem; 2005 Jan; 40(1):25-49. PubMed ID: 15642407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple N-methylation by a designed approach enhances receptor selectivity.
    Chatterjee J; Ovadia O; Zahn G; Marinelli L; Hoffman A; Gilon C; Kessler H
    J Med Chem; 2007 Nov; 50(24):5878-81. PubMed ID: 17973471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
    Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
    Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
    De Corte BL; Kinney WA; Liu L; Ghosh S; Brunner L; Hoekstra WJ; Santulli RJ; Tuman RW; Baker J; Burns C; Proost JC; Tounge BA; Damiano BP; Maryanoff BE; Johnson DL; Galemmo RA
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5227-32. PubMed ID: 15380233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
    Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
    J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents.
    Dayam R; Aiello F; Deng J; Wu Y; Garofalo A; Chen X; Neamati N
    J Med Chem; 2006 Jul; 49(15):4526-34. PubMed ID: 16854058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
    Boys ML; Schretzman LA; Chandrakumar NS; Tollefson MB; Mohler SB; Downs VL; Penning TD; Russell MA; Wendt JA; Chen BB; Stenmark HG; Wu H; Spangler DP; Clare M; Desai BN; Khanna IK; Nguyen MN; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Steininger CN; Westlin M; Westlin W; Yu YX; Wang Y; Dalton CR; Norring SA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):839-44. PubMed ID: 16298127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
    Raboisson P; Manthey CL; Chaikin M; Lattanze J; Crysler C; Leonard K; Pan W; Tomczuk BE; Marugán JJ
    Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic integrin inhibition: allosteric and activation-specific inhibition strategies may surpass the initial ligand-mimetic strategies.
    Ahrens I; Peter K
    Thromb Haemost; 2008 May; 99(5):803-4. PubMed ID: 18449408
    [No Abstract]   [Full Text] [Related]  

  • 16. Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.
    Penning TD; Khilevich A; Chen BB; Russell MA; Boys ML; Wang Y; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Rader RK; Settle SL; Shannon KE; Steininger CN; Westlin MM; Westlin WF
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3156-61. PubMed ID: 16621534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous integrin alphavbeta3 and glycoprotein IIb/IIIa inhibition causes reduction in infarct size in a model of acute coronary thrombosis and primary angioplasty.
    Sakuma T; Sari I; Goodman CN; Lindner JR; Klibanov AL; Kaul S
    Cardiovasc Res; 2005 Jun; 66(3):552-61. PubMed ID: 15914120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacophore model of integrin alphavbeta3 antagonists].
    Cheng GY; Ni GH; Jiang FC
    Yao Xue Xue Bao; 2009 Apr; 44(4):379-85. PubMed ID: 19545055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the binding epitope of RGD-peptidomimetics to αvβ3 and α(IIb)β3 integrin-rich intact cells by NMR and computational studies.
    Guzzetti I; Civera M; Vasile F; Araldi EM; Belvisi L; Gennari C; Potenza D; Fanelli R; Piarulli U
    Org Biomol Chem; 2013 Jun; 11(23):3886-93. PubMed ID: 23657523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human integrin alphavbeta5: homology modeling and ligand binding.
    Marinelli L; Gottschalk KE; Meyer A; Novellino E; Kessler H
    J Med Chem; 2004 Aug; 47(17):4166-77. PubMed ID: 15293989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.